FDA, Capricor battle over DMD cell therapy's efficacy at adcomm
The FDA and Capricor Therapeutics offered sharply opposed interpretations of clinical data backing the company's potential new cell therapy for the rare and fatal Duchenne muscular dystrophy at an advisory committee meeting Wednesday. The agency's ...
July 29, 2026 02:11 PM EDT FDA+ FDA and Capricor clash over deramiocel efficacy data at Duchenne adcomm vote Zachary Brennan Senior Editor The FDA and Capricor Therapeutics offered sharply opposed interpretations of clinical data backing the company’s potential new cell therapy for the rare and fatal Duchenne … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that